Results 131 to 140 of about 1,885,895 (335)

Imatinib resistance: a review of alternative inhibitors in chronic myeloid leukemia

Revista Brasileira de Hematologia e Hemoterapia, 2011
The development of point mutations in the BCR-ABL kinase domain is the main reason for imatinib resistance in chronic myeloid leukemia. Different detection methods are used in chronic myeloid leukemia monitoring, such as direct sequencing, denaturing ...
Roberta Bitencourt, Ilana Zalcberg, Iúri Drumond Louro   +2 more
doaj   +1 more source

Metabolism-related pharmacokinetic drug−drug interactions with tyrosine kinase inhibitors: current understanding, challenges and recommendations

British Journal of Clinical Pharmacology, 2015
Drug−drug interactions (DDIs) occur when a patient's response to the drug is modified by administration or co‐exposure to another drug. The main cytochrome P450 (CYP) enzyme, CYP3A4, is implicated in the metabolism of almost all of the tyrosine kinase ...
Yi-Ling Teo, H. Ho, A. Chan
semanticscholar   +1 more source

Protocol for quantifying miRNA trafficking across the endosomal membrane

FEBS Open Bio, EarlyView.
An in vitro protocol measures miRNA uptake into endosomes isolated from mammalian cell extracts, which are free of subcellular contaminants. Performed at 37 °C in the presence of ATP, it ensures the import of single‐stranded miRNA into the endosomal lumen.
Syamantak Ghosh, Kamalika Mukherjee, Suvendra N. Bhattacharyya   +2 more
wiley   +1 more source

Advancements in research on the cardiovascular toxicity caused by TEC family kinases inhibitors

Frontiers in Pharmacology
The tyrosine kinase expressed in hepatocellular carcinoma (TEC) family kinases (TFKs) are a subfamily of non-receptor protein tyrosine kinases (PTKs) that include five members: TEC, bruton’s tyrosine kinase (BTK), interleukin 2-inducible T-cell kinase ...
Yi Zhang, Huangxi Fu, Xingchen Kang, Zixuan Qiu, Hao Yan, Qiaojun He, Qiaojun He, Qiaojun He, Bo Yang, Bo Yang, Bo Yang, Zhifei Xu, Peihua Luo, Peihua Luo   +13 more
doaj   +1 more source

Variability in bioavailability of small molecular tyrosine kinase inhibitors.

Cancer Treatment Reviews, 2015
Small molecular tyrosine kinase inhibitors (smTKIs) are in the centre of the very quickly expanding area of personalized chemotherapy and oral applicability thereof.
M. Herbrink, B. Nuijen, J. Schellens, J. Beijnen   +3 more
semanticscholar   +1 more source

IGF2 knockout reduces but does not abolish osteosarcoma growth in vitro and in vivo

FEBS Open Bio, EarlyView.
To test whether endogenous IGF2 promotes osteosarcoma growth, IGF2 was knocked out in Saos2 cells via CRISPR‐Cas9. KO cells showed reduced proliferation in vitro, and knockout xenografts in mice reached only ~25% of wild‐type tumor volume. Insulin‐like growth factor 2 (IGF2) is implicated in osteosarcoma, but direct functional evidence of its role is ...
Shun Yao, Marco Archetti
wiley   +1 more source

Development of novel, potent and selective small molecular weight PI3K/mTOR inhibitors for the treatment of cancer [PDF]

, 2011
The phosphoinositide 3-kinases (PI3Ks) belong to a family of lipid kinases, which are implicated in signal transduction pathways and modulation of fundamental cellular activities such as cell growth, proliferation, differentiation, motility, survival and
Cmiljanović, Nataša
core   +1 more source

Development of myasthenia gravis in a patient with chronic myeloid leukemia during treatment with nilotinib

Hematology Reports, 2014
We report on a patient diagnosed with chronic myeloid leukemia (CML) who developed myasthenia gravis while on treatment with nilotinib. Autoimmune disease, including the development of myasthenia gravis, has been described in association with CML as well
David Sanford, Maria MacDonald, Michael Nicolle, Anargyros Xenocostas   +3 more
doaj   +1 more source

Uncovering G Protein‐Coupled Receptors: Novel Targets and Biomarkers for Predicting Glioma Prognosis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Low‐grade gliomas (LGG) exhibit significant heterogeneity and recurrence risk. G protein‐coupled receptors (GPCR) contribute to glioma malignant progression, but their prognostic value remains unclear. This work attempts to formulate a GPCR‐based outcome‐predicting model for LGG. Methods Based on TCGA LGG data, the enrichment scores
Jun Yang, Dongxu Zhang, Dongyuan Liu, Da Lin, Hao Wang   +4 more
wiley   +1 more source

More than a Decade of Tyrosine Kinase Inhibitors in the Treatment of Solid Tumors: What We Have Learned and What the Future Holds [PDF]

, 2015
The use of tyrosine kinase inhibitors (TKIs) in the treatment of solid tumors is the expected standard of care for many types of tumors. Since the description of signal transduction pathways, followed by the development of small molecules designed to ...
Maria Vergoulidou
core   +1 more source